Article thumbnail

Morphological Changes of Parotid Gland in Experimental Hyperlipidemia

By Ioanna D. Daskala and Christina C. Tesseromatis

Abstract

Objective. The aim of this study was to investigate the role of hyperlipidemia in the microstructure of parotid gland and its possible amelioration through statin treatment on Wistar rats. Methods. Forty Wistar rats (111.06 ± 3.36 g) were divided into 4 groups (A1, A2 controls, B1, B2 experimental). Groups A1 and A2 consumed normal cereal rodents diet during the experimental hyperlipidemic mixture. The A2 and B2 were treated with simvastatin (Zocor) 40 mg/kg/daily p.o. for 3 months. Results. Total cholesterol, triglycerides, high density lipoproteins, and low density lipoproteins were increased in groups B1 and B2 while the parotid weight was decreased. The histological findings demonstrated changes in the parotid gland morphology of the B1 and B2, such as the presence of chronic inflammation, fibrosis, lipocytes, and foci of lymphocytic infiltration. Conclusions. The influence of statin tended to predominate over the chronic inflammation while the lipocytes were decreased and remodelling of the parotid's structure occurred

Topics: Research Article
Publisher: Hindawi Publishing Corporation
OAI identifier: oai:pubmedcentral.nih.gov:3065036
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1989). a n g a n e l l i ,F .S a l a ffi, and U. Ambanelli, “Pseudo-Sjogren’s syndrome in type IV hyperlipoproteinemia. Description of a clinical case,”
  2. A simple method for the isolation and purification of total lipides from animal tissues,”TheJournalofBiologicalChemistry,vol.226,no.1,pp. 497–509, 1957.International
  3. (1969). Bilateral parotid gland enlargement and hyperlipoproteinemia,”
  4. (2005). Dekemp et al., “Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease,”
  5. (1980). Enlargement of the parotid glands and its relation to metabolic and cardiovascular changes,”
  6. (2007). F e r r e i r a ,M .C .B e r t o l a m i ,S .N .S a n t o se ta l . ,“ O n e -month therapy with simvastatin restores endothelial function in hypercholesterolemic children and adolescents,” Pediatric Cardiology,
  7. (1974). Functional studies of the parotid and pancreas glands in amyotrophic lateral sclerosis,”
  8. (2004). Gislon da Silva, “Captopril-induced bilateral parotid and submandibular sialadenitis,”
  9. (1998). Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome,”
  10. (1984). Isolation, characterisation and crystallization of deoxyribonucleaseIfrombovineandratparotidglandanditsinteractionwith rabbitskeletalmuscleactin,”EuropeanJournalofBiochemistry,
  11. (1986). Lipid accumulation in the major salivary glands of streptozotocin-diabetic rats,”
  12. (1996). Lipids in human saliva,”
  13. (2003). Morphological changes of parotid glands following adjuvant arthritis and ibuprofen treatment
  14. (2000). MR imaging of the salivary glands in sicca syndrome: comparison of lipid profiles and imaging in patients with hyperlipidemia and patients with Sjoegren syndrome,”
  15. (1971). Parotid enlargement and hyperlipidemia,”
  16. (2006). Parotid gland biopsy compared with labial biopsy in the diagnosis of patients with primary Sj¨ ogren’s syndrome,” Rheumatology Advance Access,
  17. (1997). Premature fat deposition in the salivary glands associated with Sjogren syndrome:
  18. (1977). Pseudo Sjogren syndrome with hyperlipoproteinemia,”
  19. (1989). Pseudo-Sjogren’s syndrome in type IV hyperlipoproteinemia. Description of a clinical case,”
  20. (1986). regarding the protection of animals used for experimental and other scientific purposes(86/609/EEC),” http://www.europa.eu/enviroment/protection of nature and biodiversity/protection of animals used for experimental purposes.
  21. (2005). Reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investigators. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease,” The New England
  22. (1996). Reversible parotid enlargement and pseudosj¨ ogren’s syndrome secondary to hypertriglyceridemia,”
  23. (2007). Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis,”
  24. (1986). Sterol composition and biosynthesis in mouse salivary glands,”
  25. (1996). The changes in the rat parotid glands following total parenteral nutrition and pancreatico-biliary diversion are not mediated by cholecystokinin,”
  26. (1997). Toide et al., “Impaired beta-cell function and deposition of fat droplets in the pancreas as a consequence of hypertriglyceridemia
  27. (1998). Triglycerides and atherogenic lipoproteins: rationale for lipid management,”
  28. (2007). W o n ,W .J .C o t t r e l l ,T .H .F o s t e r ,a n dD .I .Y u l e ,“ C a 2 + release dynamics in parotid and pancreatic exocrine acinar cells evoked by spatially limited flash photolysis,”
  29. (2004). Wegener’s granulomatosis presenting as unilateral parotid enlargement,”